Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.50 |
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | NPC1 | O15118 | 6/20 | 0.50 |
| ▸ | GAA | P10253 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | RECQL | P46063 | 2/20 | 0.50 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.50 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.50 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 8/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.49 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4601039 | 0.82 | MEN1 (0.54) | RAB9AMAPTNPC1GAAKDM4E | |
| SCHEMBL4600989 | 0.81 | SMN1; SMN2 (0.58) | RAB9AMAPTNPC1GAAMAPK1 | |
| SCHEMBL4600345 | 0.81 | KDR (0.51) | MAPK13MAPK12MAPK11MAPK14PTGS2 | |
| SCHEMBL4601257 | 0.81 | KDR (0.53) | RAB9AMAPTKDM4ENPSR1MAPK13 | |
| SCHEMBL14066778 | 0.80 | FBP1 (0.46) | RAB9AMAPTNPC1MEN1KMT2A | |
| SCHEMBL4601246 | 0.80 | KDR (0.47) | KDR | |
| SCHEMBL6278432 | 0.80 | SMN1; SMN2 (0.60) | RAB9AMAPTNPC1KDM4EMAPK1 | |
| SCHEMBL3602012 | 0.79 | KDR (0.59) | RAB9AMAPTNPC1GAAKDM4E | |
| SCHEMBL14066777 | 0.78 | KDR (0.50) | RAB9AKDM4EMAPK13MAPK12MAPK11 | |
| SCHEMBL4601915 | 0.78 | KDR (0.50) | RAB9AMAPTNPC1GAAMAPK13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227783-A1 | 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-18 | — | — | US | claimed |
| EP-1912959-A2 | 5-SUBSTITUTED THIAZOL-2-YL AMINO COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-04-23 | — | — | EP | claimed |
| WO-2007016228-A2 | 5-SUBSTITUTED THIAZOL-2-YL AMINO COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-02-08 | — | — | WO | claimed |
| EP-1687285-B1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-03-05 | — | — | EP | disclosed |
| EP-1687285-B1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-03-05 | — | — | EP | disclosed |
| US-7795288-B2 | Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-7795288-B2 | Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-7795288-B2 | Thiazole and pyrazole derivatives as Flt-3 kinase inhibitors | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-20080227783-A1 | 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-18 | — | — | US | disclosed |
| US-20080227783-A1 | 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-18 | — | — | US | disclosed |
| US-20080227783-A1 | 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors | IRM LLC (BM) | 2008-09-18 | — | — | US | disclosed |
| EP-1912959-A2 | 5-SUBSTITUTED THIAZOL-2-YL AMINO COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-04-23 | — | — | EP | disclosed |
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | NOVARTIS PHARMA AG (CH) | 2007-07-19 | — | — | US | disclosed |
| WO-2007016228-A2 | 5-SUBSTITUTED THIAZOL-2-YL AMINO COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-02-08 | — | — | WO | disclosed |
| WO-2007016228-A2 | 5-SUBSTITUTED THIAZOL-2-YL AMINO COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2007-02-08 | — | — | WO | disclosed |
| EP-1687285-A1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | Novartis AG (CH) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005047273-A1 | THIAZOLE AND PYRAZOLE DERIVATIVES AS FLT-3 KINASE INHIBITORS | NOVARTIS AG (CH) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167449-A1 | Thiazole and pyrazole derivatives as flt-3 kinase inhibitors | FLT3, FLT1, FLT4 | RAB9A 3667/4885MAPT 3162/4885NPC1 3464/4885 |
| US-20080227783-A1 | 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors | BMX, CDK1, CKS1B | RAB9A 4092/4885MAPT 1305/4885NPC1 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.